

# ASX Announcement

Medibio Limited – 11 November 2022

## AGM CHAIR'S ADDRESS

**Melbourne, Australia and Minneapolis, MN – 11 November 2022: Medibio Limited (MEB or the Company) (ASX: MEB) (OTCPINK: MDBIF), is pleased to release the Chair address to be made at the Annual General Meeting (AGM) to be held at 8.30am (AEDT) today.**

### Chair Address

It is with great pleasure that I recently took over the role as Independent Non-Executive Chair at Medibio Limited.

I have been in the role for a short period of time now and after gaining some insights into where the Company is currently positioned and its current product mix, I am excited about the future.

There is no doubt there have been some significant challenges in the past few years and while it may have taken longer than we all would have liked to resolve some of these issues, we firmly believe they are behind us and the board and management can now focus on growing our business and making a significant positive impact in people's lives by introducing an extremely innovative, scientific based approach to mental illness and its detection and diagnosis.

In coming in as Chair it was imperative to me that there was in essence a clean slate and having a new CEO in Dr Tom Young with his industry experience and commercial minded ideology, makes me excited that we can commercialise Medibio's IP and work to ensure shareholders are rewarded for their tireless patience they have placed in the Medibio board.

It is my sincere promise that the board will now keep shareholders fully informed on our progress and be readily available to provide updates on strategy and commercialisation on a regular basis. We have not forgotten about the past and the issues we uncovered in Medibio however, we look forward now and will ensure those mistakes will never happen again.

I will allow Tom to provide shortly an operational update but I look forward to the future at Medibio and believe the next 12 months will be significantly better for shareholders, our stakeholders and management.

ENDS

*This announcement is authorised for release to the market by the Board of Directors of Medibio Limited.*

### **About Medibio Limited**

Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The Company was founded in Australia, with offices located in Melbourne (Vic) and Minneapolis (MN). Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on [www.otcm Markets.com](http://www.otcm Markets.com) and [www.asx.com.au](http://www.asx.com.au).

### **Medibio Investor Enquiries:**

Medibio Investor Relations  
[investors@medibio.com.au](mailto:investors@medibio.com.au)  
+61 3 9692 7222

Level 4, 100 Albert Road, South Melbourne, Vic 3205  
Email: [info@medibio.com.au](mailto:info@medibio.com.au) | [www.medibio.com.au](http://www.medibio.com.au)